KTOV actually has a billion dollar drug on hand. float is tiny and insiders buying nonstop.cap is a joke relating sales predictions. Rodman & Renshaw ,believes its leading product, KIT-302, has the potential to reach blockbuster status in the US alone. even on $50 cap will be still very reasonable about $200m. We are talking about the same Celebrex ($1.7B in average,2014-2015 sales) but with limited side effects. The company has no debt, no need to raise cash due P3 declared final and target was fully achieved. if we take only 10%-20% of their market share alone,on 70% profit margin will brings us to $200 net income per year. 9 times market cap($22m current cap) might be equal to only one year net income. calculate PV and you ended up with a present value of $1B+. a major pharma can plop down $200m- $300m on a buyout for a billion dollar risk reward as well even before the drug hit the market (2017),imo.this might be Pfizer or another big Pharma imo.
Solid Management including a former FDA chemist and a former FDA medical officer.
News 
Market Data 
Discover 
